Previous 10 | Next 10 |
CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today an...
CAMBRIDGE, Mass., May 04, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, tod...
CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, to...
Checkmate Pharmaceuticals, Inc. is a small clinical-stage biotech focused on the immune-system-based therapeutic development for combating cancer, particularly targeting TLR9 of pDCs with virus-like delivery. Checkmate Pharmaceuticals currently has one therapeutic in their pipeline kn...
CAMBRIDGE, Mass., April 19, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, to...
The following slide deck was published by Checkmate Pharmaceuticals, Inc. in conjunction with this event. For further details see: Checkmate Pharmaceuticals (CMPI) Presents At AACR Virtual Meeting 2021 - Slideshow
Gainers: Wilhelmina International (WHLM) +44%.180 Life Sciences (ATNF) +28%.Evelo Biosciences (EVLO) +24%.Celcuity (CELC) +19%.Taysha Gene Therapies (TSHA) +17%.Nuance Communications (NUAN) +16%.Tiziana Life Sciences (TLSA) +15%.PLBY Group (PLBY) +13%.Pintec Technology (PT) +13%.Aur...
Checkmate Pharmaceuticals (CMPI) presents new translational data from its Phase 1b trial of vidutolimod (CMP-001) in combination with pembrolizumab in patients with advanced anti-PD-1 refractory melanoma. Response rates to vidutolimod in combination with pembrolizumab were similar across base...
CAMBRIDGE, Mass., April 11, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today ...
Today, we become the first Seeking Alpha contributor to put Checkmate Pharmaceuticals in the spotlight since its IPO last summer. The company is focused on harnessing the power of one’s immune system to fight cancer. A full analysis on Checkmate Pharmaceuticals follows in t...
News, Short Squeeze, Breakout and More Instantly...
Checkmate Pharmaceuticals Inc. Company Name:
CMPI Stock Symbol:
NASDAQ Market:
Checkmate Pharmaceuticals Inc. Website:
Ad-hoc announcement pursuant to Article 53 of the SIX listing rules • $2.5 million of milestone to be paid to XOMA Corporation under royalty agreement SCHLIEREN (ZURICH), Switzerland, June 02, 2022 (GLOBE NEWSWIRE) -- Kuros Biosciences AG (“Kuros” ...
CAMBRIDGE, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat c...
CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (Nasdaq: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today an...